Senior level executive and commercial leader with over 25 years of sales leadership and marketing experience in the medical and healthcare industry with vast experience in new product development, strategy consulting, research, product launch, medical device start-up, fund raising, and medical device management as well as medical device experience in strategy, business development, and marketing roles. I am currently serving as President & Chief Operating Officer for MYOCARDIAL SOLUTIONS, INC. - a highly innovative start-up cardiovascular diagnostics software company, focusing on the launch of a commercially available, proprietary and non-invasive quantitative heart function assessment test called MyoStrain® - a new, rapid MRI-based heart function test that quantifies the effects of disease, drugs, and ischemia across 48 heart segments in under 10 minutes! Myocardial Solutions, Inc. (MSI), is a Biotech Software Company whose mission is to give cardiac and oncology patients control over their heart health. By quantifying subtle changes in myocardial heart function, MSI's proprietary MyoStrain® technology provides a standardized, proactive approach to help physicians effectively detect, monitor, and manage the early progression of myocardial dysfunction and prevent heart failure. Combined with its speed and efficiency, MyoStrain® may provide a critical population management tool to help physicians individualize cardiac treatment for at-risk patient populations in cardiology and oncology. With 80,000+ patient data points from over 70 medical centers in the United States and EU, MyoStrain® has been rigorously validated in over 500+ publications, including 50+ in JACC and Circulation. The MyoStrain® heart function test is a rapid, non-invasive MRI scan performed in under 10 minutes and has been optimized for clinical use due to its speed, ease of use, and quantitative accuracy.